These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 6141616)

  • 1. Are the pharmacological effects of L-prolyl-L-leucyl-glycinamide (PLG) mediated through specific receptor mechanisms?
    Chiu S; Wong YW; Wan YP; Chiu P; Mishra RK
    Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(4-6):739-42. PubMed ID: 6141616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CNS putative L-prolyl-L-leucyl-glycinamide (PLG) receptors, brain and lymphocyte dopamine receptors.
    Chiu S; Ferris JA; Johnson R; Mishra RK
    Prog Neuropsychopharmacol Biol Psychiatry; 1982; 6(4-6):365-8. PubMed ID: 6298884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attenuation of SCH 23390-induced alteration of striatal dopamine D1 receptor ontogeny by prolyl-leucyl-glycinamide in the rat.
    Kostrzewa RM; Saleh MI
    Neuropharmacology; 1989 Aug; 28(8):805-10. PubMed ID: 2571103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of L-prolyl-L-leucyl-glycinamide (PLG) on neuroleptic-induced catalepsy and dopamine/neuroleptic receptor bindings.
    Chiu S; Paulose CS; Mishra RK
    Peptides; 1981; 2(1):105-11. PubMed ID: 6113579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of L-prolyl-L-leucyl glycinamide with dopamine D2 receptor: evidence for modulation of agonist affinity states in bovine striatal membranes.
    Srivastava LK; Bajwa SB; Johnson RL; Mishra RK
    J Neurochem; 1988 Mar; 50(3):960-8. PubMed ID: 2892892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Down-regulation of haloperidol-induced striatal dopamine receptor supersensitivity by active analogues of L-prolyl-L-leucyl-glycinamide (PLG).
    Rajakumar G; Naas F; Johnson RL; Chiu S; Yu KL; Mishra RK
    Peptides; 1987; 8(5):855-61. PubMed ID: 2893360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroleptic drug-induced dopamine receptor supersensitivity: antagonism by L-prolyl-L-leucyl-glycinamide.
    Chiu S; Paulose CS; Mishra RK
    Science; 1981 Dec; 214(4526):1261-2. PubMed ID: 6117947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mesolimbic and striatal dopamine receptor supersensitivity: prophylactic and reversal effects of L-prolyl-L-leucyl-glycinamide (PLG).
    Chiu P; Rajakumar G; Chiu S; Johnson RL; Mishra RK
    Peptides; 1985; 6(2):179-83. PubMed ID: 2863809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the oxytocin fragment prolyl-leucyl-glycinamide on sexual behavior in the rat.
    Gorzalka BB; Luck KA; Tanco SA
    Pharmacol Biochem Behav; 1991 Feb; 38(2):273-9. PubMed ID: 1676168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of agonist binding to human dopamine receptor subtypes by L-prolyl-L-leucyl-glycinamide and a peptidomimetic analog.
    Verma V; Mann A; Costain W; Pontoriero G; Castellano JM; Skoblenick K; Gupta SK; Pristupa Z; Niznik HB; Johnson RL; Nair VD; Mishra RK
    J Pharmacol Exp Ther; 2005 Dec; 315(3):1228-36. PubMed ID: 16126839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of dopaminergic neurotransmission in the 6-hydroxydopamine lesioned rotational model by peptidomimetic analogues of L-prolyl-L-leucyl-glycinamide.
    Ott MC; Mishra RK; Johnson RL
    Brain Res; 1996 Oct; 737(1-2):287-91. PubMed ID: 8930377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of CNS dopamine receptors by peptides.
    Mishra RK
    Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(4-6):437-42. PubMed ID: 6141599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. L-prolyl-L-leucyl-glycinamide analogues--a new class of peptide antihypertensives.
    Rajakumar G; Singh AN; Naas F; Chiu S; Kwan CY; Johnson RL; Mishra RK
    J Hypertens Suppl; 1986 Dec; 4(5):S106-8. PubMed ID: 2883271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potentiation of apomorphine action in rats by l-prolyl-l-leucyl-glycine amide.
    Kostrzewa RM; Kastin AJ; Sobrian SK
    Pharmacol Biochem Behav; 1978 Sep; 9(3):375-8. PubMed ID: 30981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The action of prolyl-leucyl-glycinamide (PLG) on the nigrostriatal pathway of the rat.
    Pereira JS; Andrade LA; Bertolucci PH; Lima JG; Ferraz HB
    Arq Neuropsiquiatr; 1990 Jun; 48(2):156-60. PubMed ID: 1979732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. L-prolyl-l-leucyl-glycinamide and its peptidomimetic analog 3(R)-[(2(S)-pyrrolidylcarbonyl)amino]-2-oxo-1-pyrrolidineacetamide (PAOPA) attenuate haloperidol-induced c-fos expression in the striatum.
    Ott MC; Costain WJ; Mishra RK; Johnson RL
    Peptides; 2000 Feb; 21(2):301-8. PubMed ID: 10764960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vasopressin release by D-aspartic acid, morphine and prolyl-leucyl-glycinamide (PLG) in DI Brattleboro rats.
    Koyuncuoğlu H; Berkman K; Hatipoğlu I; Sabuncu H
    Pharmacol Biochem Behav; 1984 Apr; 20(4):519-25. PubMed ID: 6145163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potentiation of apomorphine-induced stereotypies by naloxone and L-prolyl-L-leucyl-glycinamide.
    Quock RM; Lucas TS; Hartl TJ
    Pharmacol Biochem Behav; 1983 Jul; 19(1):49-52. PubMed ID: 6137836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding studies of L-prolyl-L-leucyl-glycinamide (PLG), a novel antiparkinsonian agent, in normal human brain.
    Chiu S; Wong YW; Ferris JA; Johnson RL; Mishra RK
    Pharmacol Res Commun; 1983 Jan; 15(1):41-51. PubMed ID: 6131441
    [No Abstract]   [Full Text] [Related]  

  • 20. Dopamine receptor modulation by Pro-Leu-Gly-NH2 analogues possessing cyclic amino acid residues at the C-terminal position.
    Johnson RL; Rajakumar G; Mishra RK
    J Med Chem; 1986 Oct; 29(10):2100-4. PubMed ID: 2876103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.